Outcome of acute ischemic stroke in very elderly patients: is intravenous thrombolysis beneficial?

Eur Neurol. 2011;66(2):110-6. doi: 10.1159/000328429. Epub 2011 Aug 18.

Abstract

Background/aims: Intravenous tissue plasminogen activator (tPA) treatment is recommended in acute stroke within 3 h of onset; however, the benefit of its use in the elderly remains uncertain. We assessed the safety and efficacy of tPA treatment in elderly patients.

Methods: We recruited 97 elderly Chinese patients aged ≥80 years with cerebral ischemia presenting within 3 h of onset. Favorable outcomes were defined as discharge to home and modified Rankin Scale (mRS) ≤2 at discharge.

Results: For moderate to severe patients (NIHSS ≥6), the baseline characteristics between the tPA (n = 30) and non-tPA (n = 41) group were not different. The proportion of patients discharged home was 56.7 and 61%, respectively (p = 0.72). For patients with baseline mRS ≤2, the frequency of discharged mRS ≤2 was not different (27.3% of the tPA group and 26.9% of the non-tPA group; p = 1.00). Symptomatic intracranial hemorrhage was 6.7 and 2.4%, respectively (p = 0.31). For minor stroke patients (NIHSS ≤5), tPA was not considered and the outcome of those discharged home and mRS ≤2 was 73 and 88%, respectively.

Conclusion: Elderly patients can be treated safely with intravenous tPA, whereas our data did not support routine thrombolysis. Further randomized trials in the elderly are encouraged.

MeSH terms

  • Aged, 80 and over
  • Brain / metabolism
  • Brain / pathology
  • Female
  • Humans
  • Injections, Intravenous
  • Ischemic Attack, Transient / drug therapy*
  • Male
  • Neurologic Examination
  • Retrospective Studies
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Stroke / drug therapy*
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome

Substances

  • Tissue Plasminogen Activator